Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers.

Cancer Cell Int · 2022 · PMC8896121 · PMID 35241075

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results indicated that when the pathological stage increased, LMNB1 expression showed a trend of gradual increase in ACC (Adrenocortical carcinoma), KIRC, LUAD, TGCT (Testicular Germ Cell Tumors), and a trend of gradual decrease in OV, while no obvious gradual trend but with stage-specific expression difference in KICH, KIRP, LIHC and SKCM (Fig. 1 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.